<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="(CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract The currently available drugs against" exact="influenza" post="A virus primarily target neuraminidase (NA) or the matrix"/>
 <result pre="termed NC-5, was found to possess antiviral activity. NC-5 inhibited" exact="influenza" post="A viruses A/FM/1/47 (H1N1), A/Beijing/32/92 (H3N2) and oseltamivir-resistant mutant"/>
 <result pre="regarded as a promising drug candidate to treat infection with" exact="influenza" post="viruses, including oseltamivir-resistant viruses. benzoic acid derivatives antiviral activity"/>
 <result pre="acid derivatives antiviral activity neuraminidase inhibition oseltamivir-resistant 1. Introduction The" exact="influenza" post="A virus belongs to the Orthomyxoviridae family and is"/>
 <result pre="severe epidemics of respiratory illness [1]. The genome of the" exact="influenza" post="virus contains eight segmented and negative-stranded RNAs, encoding for"/>
 <result pre="cells [6,7]. However, due to the frequent emergence of drug-resistant" exact="influenza" post="viruses, the usage of these drugs has been greatly"/>
 <result pre="molecule, was reported to show sub-micromolar antiviral potency against the" exact="influenza" post="A virus [11,12]. Some compounds have been successfully designed"/>
 <result pre="designed a series of benzoic acid derivatives to obtain potential" exact="influenza" post="virus inhibitors with improved antiviral activity. In our research,"/>
 <result pre="possess a triazole substituent had been reported to inhibit the" exact="influenza" post="virus via insertion into the 150-cavity near the active"/>
 <result pre="compounds that displayed a reduction in the CPE on the" exact="influenza" post="H1N1 virus at 10 μM and 100 μM (Table"/>
 <result pre="as the CHO-K1 expression of NA proteins of highly pathogenic" exact="avian influenza" post="viruses H5N1 (Figure 2D) and H7N9 (Figure 2C) were"/>
 <result pre="the CHO-K1 expression of NA proteins of highly pathogenic avian" exact="influenza" post="viruses H5N1 (Figure 2D) and H7N9 (Figure 2C) were"/>
 <result pre="of the CPE reduction assay (Table 1), we tested other" exact="influenza" post="virus strains including an oseltamivir-resistant strain to confirm the"/>
 <result pre="h post-infection in a dose-dependent manner, indicating that NC-5 inhibits" exact="influenza" post="virus infection by interfering with viral replication. This result"/>
 <result pre="indicate that NC-5 effectively inhibits both wild-type and oseltamivir-resistant mutant" exact="influenza" post="viruses in vitro and could reduce the level of"/>
 <result pre="was designed to evaluate the efficacy of NC-5 against the" exact="influenza" post="virus in vivo. Body weight, survival and clinical manifestations"/>
 <result pre="demonstrates potent therapeutic efficacy in vivo against wild-type and oseltamivir-resistant" exact="influenza" post="viruses. 2.5. NC-5 Suppressed Influenza Virus A/FM/1/47 (H1N1) in"/>
 <result pre="tried to explore the potential mechanisms by which NC-5 inhibits" exact="influenza" post="infection. The complete life cycle of the influenza virus"/>
 <result pre="NC-5 inhibits influenza infection. The complete life cycle of the" exact="influenza" post="virus is approximately 8–10 h and it is divided"/>
 <result pre="displays anti-influenza virus activity in vitro and in vivo. The" exact="influenza" post="virus produces clear and rapid CPE following cell death"/>
 <result pre="(EC50) values of 33.6 μM and 32.8 μΜ. However, for" exact="influenza" post="virus H3N2, the EC50 value was greater than 160"/>
 <result pre="All the data demonstrate that NC-5 possesses potent activity against" exact="influenza" post="viruses, including oseltamivir-resistant viruses. Nucleoprotein (NP) and matrix protein"/>
 <result pre="mechanism of antiviral activity, we found that the activity against" exact="influenza" post="virus took effect in the biosynthesis stage with the"/>
 <result pre="respectively. It has been reported that the resistance mutations of" exact="influenza" post="virus H1N1 mostly occur at His275 and Arg292 sites"/>
 <result pre="in DMEM/F12 medium supplemented with 10% FBS. Virus production: The" exact="influenza" post="A virus used in this study, containing A/FM/1/47 (H1N1),"/>
 <result pre="Lipofectamine® 2000 Reagent (Invitrogen™, Carlsbad, CA, USA). Expression plasmids for" exact="influenza" post="A virus A/WSN/33 (H1N1) proteins (PB1, PB2, PA and"/>
 <result pre="virus A/WSN/33 (H1N1) proteins (PB1, PB2, PA and NP), an" exact="influenza" post="virus-like RNA encoding firefly luciferase (vNS-Luc), and pCMV β-gal"/>
 <result pre="stock solution. 4.3. Determination of Influenza a Virus TCID50 The" exact="influenza" post="A virus was serially diluted and added to specific"/>
 <result pre="of a suspension of 8 × LD50 of the mouse-adapted" exact="influenza" post="A/FM1/1/47 (H1N1), A/FM/1/47-H275Y virus diluted in phosphate-buffered saline (PBS)."/>
 <result pre="were infected with 1.5 × 103 TCID50 of the H1N1" exact="influenza" post="virus and treated with NC-5 (10 μM, 40 μM,"/>
 <result pre="24-well plate and then transfected with plasmids to express the" exact="influenza" post="A virus A/WSN/33 (H1N1) PB1, PB2, PA, NP and"/>
 <result pre="and infected with 1.5 × 103 TCID50 of the H1N1" exact="influenza" post="virus for 2 h followed by the addition of"/>
 <result pre="and infected with 1.5 × 103 TCID50 of the H1N1" exact="influenza" post="virus for 2 h then treated with NC-5 (10"/>
 <result pre="diethyl triazole benzoic acid derivative, NC-5. This compound can inhibit" exact="influenza" post="A viruses A/FM/1/47 (H1N1), A/Beijing/32/92 (H3N2) and oseltamivir-resistant mutant"/>
 <result pre="Therefore, it can be regarded as a promising candidate for" exact="influenza" post="virus infection therapy. Its modification to improve the efficacy,"/>
 <result pre="Abbreviations NC-5 4-[2,2-bis(hydroxymethyl)-5-oxopyrrolidin-l-yl]-3-(5-cyclohexyl-4H-1, 2,4-triazol-3-yl) amino) benzoic acid NA neuraminidase H1N1" exact="influenza" post="A virus A/FM/1/47 (H1N1) H1N1-H275Y influenza A virus A/FM/1/47-H275Y"/>
 <result pre="acid NA neuraminidase H1N1 influenza A virus A/FM/1/47 (H1N1) H1N1-H275Y" exact="influenza" post="A virus A/FM/1/47-H275Y (H1N1-H275Y) H3N2 influenza A virus A/Beijing/32/92"/>
 <result pre="virus A/FM/1/47 (H1N1) H1N1-H275Y influenza A virus A/FM/1/47-H275Y (H1N1-H275Y) H3N2" exact="influenza" post="A virus A/Beijing/32/92 (H3N2) H5N1 influenza A virus A/Vietnam/1203/2004"/>
 <result pre="virus A/FM/1/47-H275Y (H1N1-H275Y) H3N2 influenza A virus A/Beijing/32/92 (H3N2) H5N1" exact="influenza" post="A virus A/Vietnam/1203/2004 (H5N1) H7N9 influenza A virus A/Anhui/1/2013"/>
 <result pre="virus A/Beijing/32/92 (H3N2) H5N1 influenza A virus A/Vietnam/1203/2004 (H5N1) H7N9" exact="influenza" post="A virus A/Anhui/1/2013 (H7N9) H7N9-R294K influenza A virus A/Anhui/1/2013-R294K"/>
 <result pre="virus A/Vietnam/1203/2004 (H5N1) H7N9 influenza A virus A/Anhui/1/2013 (H7N9) H7N9-R294K" exact="influenza" post="A virus A/Anhui/1/2013-R294K (H7N9-R294K MDCK Madin–Darby canine kidney cells"/>
 <result pre="Pentacyclic Triterpenoids as Potential Entry Inhibitors of InfluenzaViruses201457100581007110.1021/jm501406725383779 2.SuzukiY.Sialobiology of" exact="influenza" post="molecular mechanism of host range variation of influenza virusesBiol."/>
 <result pre="2.SuzukiY.Sialobiology of influenza molecular mechanism of host range variation of" exact="influenza" post="virusesBiol. Pharm. Bull.20052839940810.1248/bpb.28.39915744059 3.LeeS.M.Y.YenH.L.Targeting the host or the virus:"/>
 <result pre="the virus: Current and novel concepts for antiviral approaches against" exact="influenza" post="virus infectionAntivir. Res.20129639140410.1016/j.antiviral.2012.09.01323022351 4.RudrawarS.DyasonJ.C.Rameix-WeltiM.A.RoseF.J.KerryP.S.RussellR.J.van der WerfS.ThomsonR.J.NaffakhN.von ItzsteinM.Novel sialic acid"/>
 <result pre="ItzsteinM.Novel sialic acid derivatives lock open the 150-loop of an" exact="influenza" post="A virus group-1 sialidaseNat. Commun.2010111310.1038/ncomms111421081911 5.RussellR.J.HaireL.F.StevensD.J.CollinsP.J.LinY.P.BlackburnG.M.HayA.J.GamblinS.J.SkehelJ.J.J.N.The structure of H5N1"/>
 <result pre="influenza A virus group-1 sialidaseNat. Commun.2010111310.1038/ncomms111421081911 5.RussellR.J.HaireL.F.StevensD.J.CollinsP.J.LinY.P.BlackburnG.M.HayA.J.GamblinS.J.SkehelJ.J.J.N.The structure of H5N1" exact="avian influenza" post="neuraminidase suggests new opportunities for drug designNature2006443454910.1038/nature0511416915235 6.VonitzsteinM.WuW.Y.KokG.B.PeggM.S.DyasonJ.C.JinB.PhanT.V.SmytheM.L.WhiteH.F.OliverS.W.et al.Rational"/>
 <result pre="A virus group-1 sialidaseNat. Commun.2010111310.1038/ncomms111421081911 5.RussellR.J.HaireL.F.StevensD.J.CollinsP.J.LinY.P.BlackburnG.M.HayA.J.GamblinS.J.SkehelJ.J.J.N.The structure of H5N1 avian" exact="influenza" post="neuraminidase suggests new opportunities for drug designNature2006443454910.1038/nature0511416915235 6.VonitzsteinM.WuW.Y.KokG.B.PeggM.S.DyasonJ.C.JinB.PhanT.V.SmytheM.L.WhiteH.F.OliverS.W.et al.Rational"/>
 <result pre="anti-influenza activityJ. Am. Chem Soc.199711968169010.1021/ja963036t16526129 8.BrightR.A.MedinaM.J.XuX.Y.Perez-OronozG.WallisT.R.DavisX.H.M.PovinelliL.CoxN.J.KlimovA.I.Incidence of adamantane resistance among" exact="influenza" post="A (H3N2) viruses isolated worldwide from 1994 to 2005:"/>
 <result pre="A cause for concernLancet20053661175118110.1016/S0140-6736(05)67338-216198766 9.DeydeV.M.XuX.Y.BrightR.A.ShawM.SmithC.B.ZhangY.ShuY.L.GubarevaL.V.CoxN.J.KlimovA.I.Surveillance of resistance to adamantanes among" exact="influenza" post="A(H3N2) and A(H1N1) viruses isolated worldwideJ. Infect. Dis.200719624925710.1086/51893617570112 10.MosconaA.Global"/>
 <result pre="Oseltamivir-Resistant InfluenzaNew Engl. J. Med.200936095395610.1056/NEJMp090064819258250 11.SunC.W.HuangH.FengM.Q.ShiX.L.ZhangX.D.ZhouP.A novel class of potent" exact="influenza" post="virus inhibitors: Polysubstituted acylthiourea and its fused heterocycle derivativesBioorg."/>
 <result pre="13.TarbetE.B.HamiltonS.VollmerA.H.LuttickA.NgW.C.PryorM.HurstB.L.CrawfordS.SmeeD.F.TuckerS.P.A zanamivir dimer with prophylactic and enhanced therapeutic activity against" exact="influenza" post="virusesJ. Antimicrob. Chemoth.2014692164217410.1093/jac/dku12724777908 14.LiuK.C.FangJ.M.JanJ.T.ChengT.J.R.WangS.Y.YangS.T.ChengY.S.E.WongC.H.Enhanced Anti-influenza Agents Conjugated with Anti-inflammatory"/>
 <result pre="Conjugated with Anti-inflammatory ActivityJ. Med. Chem.2012558493850110.1021/jm300984422963087 15.AtigaddaV.R.BrouilletteW.J.DuarteF.AliS.M.BabuY.S.BantiaS.ChandP.ChuN.MontgomeryJ.A.WalshD.A.et al.Potent inhibition of" exact="influenza" post="sialidase by a benzoic acid containing a 2-pyrrolidinone substituentJ."/>
 <result pre="and nuclear-cytoplasmic transport of virus-specific RNAsJ. Virol.1987617647733806797 17.AtkinsC.EvansC.W.WhiteE.L.NoahJ.W.Screening methods for" exact="influenza" post="antiviral drug discoveryExpert. Opin. Drug. Dis.2012742943810.1517/17460441.2012.674510 18.AmaroR.E.SwiftR.V.VotapkaL.LiW.W.WalkerR.C.BushR.M.Mechanism of 150-cavity"/>
 <result pre="drug discoveryExpert. Opin. Drug. Dis.2012742943810.1517/17460441.2012.674510 18.AmaroR.E.SwiftR.V.VotapkaL.LiW.W.WalkerR.C.BushR.M.Mechanism of 150-cavity formation in" exact="influenza" post="neuraminidaseNat. Commun.2011210.1038/ncomms1390 19.WangW.L.LiR.Q.DengY.LuN.ChenH.MengX.WangW.WangX.P.YanK.X.QiX.R.et al.Protective Efficacy of the Conserved NP,"/>
 <result pre="Vaccine. Immunol.20152261863010.1128/CVI.00091-1525834017 20.HurtA.C.The epidemiology and spread of drug resistant human" exact="influenza" post="virusesCurr. Opin. Virol.20148222910.1016/j.coviro.2014.04.00924866471 21.YuJ.WangD.C.JinJ.XuJ.LiM.W.WangH.DouJ.ZhouC.L.Antiviral activity of SA-2 against influenza"/>
 <result pre="human influenza virusesCurr. Opin. Virol.20148222910.1016/j.coviro.2014.04.00924866471 21.YuJ.WangD.C.JinJ.XuJ.LiM.W.WangH.DouJ.ZhouC.L.Antiviral activity of SA-2 against" exact="influenza" post="A virus in vitro/vivo and its inhibition of RNA"/>
 <result pre="of RNA polymeraseAntivir. Res.2016127687810.1016/j.antiviral.2016.01.01126802558 22.ZhangJ.J.LiuT.TongX.M.LiG.YanJ.H.YeX.Identification of novel virus inhibitors by" exact="influenza" post="A virus specific reporter cell based screeningAntivir. Res.201293485410.1016/j.antiviral.2011.10.01422057306 23.ZhouC.L.JinJ.ZhangH.X.DouJ.WangD.C.JiaY.B.Synthesis"/>
 <result pre="cells during mouse embryogenesisNat. Genet.20033317217610.1038/ng107212524542 25.DingY.DouJ.TengZ.J.YuJ.WangT.T.LuN.WangH.ZhouC.L.Antiviral activity of baicalin against" exact="influenza" post="A (H1N1/H3N2) virus in cell culture and in mice"/>
 <result pre="inhibition of neuraminidaseArch. Virol.20141593269327810.1007/s00705-014-2192-225078390 26.DongW.J.WeiX.L.ZhangF.Y.HaoJ.F.HuangF.ZhangC.L.LiangW.A dual character of flavonoids in" exact="influenza" post="A virus replication and spread through modulating cell-autonomous immunity"/>
 <result pre="benzoic acid. Figure 2 The inhibitory activity of NC-5 on" exact="influenza" post="A virus neuraminidase (NA). (A) NA-inhibitory effect on A/FM/1/47"/>
 <result pre="Figure 3 Inhibitory effect of NC-5 on wild-type and oseltamivir-resistant" exact="influenza" post="A virus in Madin–Darby canine kidney (MDCK) cells. (A)"/>
 <result pre="cells. (B) The inhibition rate of NC-5 (10–160 μM) on" exact="influenza" post="A virus A/FM/1/47 (H1N1) and A/Beijing/32/92 (H3N2). MDCK cells"/>
 <result pre="control. (C) The inhibition rate of NC-5 (20–80 μM) against" exact="influenza" post="A virus H1N1 in MDCK cells at different TCID50."/>
 <result pre="TCID50. (D) The inhibition rate of NC-5 (20–80 μM) against" exact="influenza" post="A virus H3N2 in MDCK cells at different TCID50."/>
 <result pre="mean ± S.D. of three independent experiments. Figure 4 NC-5" exact="suppression" post="of A/FM/1/47 (H1N1) influenza viral replication and its effect"/>
 <result pre="three independent experiments. Figure 4 NC-5 suppression of A/FM/1/47 (H1N1)" exact="influenza" post="viral replication and its effect on NP and M1"/>
 <result pre="with A/FM/1/47 (H1N1) virus. The ICR mice were infected with" exact="influenza" post="A virus (8 × LD50), and ten mice in"/>
 <result pre="Therapeutic effect of NC-5 on mice infected with the oseltamivir-resistant" exact="influenza" post="A virus A/FM/1/47-H275Y (H1N1-H275Y). The ICR mice were intranasally"/>
 <result pre="&amp;lt;0.001 compared with the placebo group. Figure 7 NC-5 suppressed" exact="influenza" post="A virus replication by inhibiting NP and M1 protein"/>
 <result pre="293T cells transfected with plasmids containing PB1, PB2, PA, NP," exact="influenza" post="virus-like RNA encoding firefly luciferase (vNS-Luc) and pCMV β-gal"/>
 <result pre="compared with the DMSO control. ijms-20-06261-t001_Table 1Table 1 Structures and" exact="influenza" post="A virus inhibition rates of newly synthesized compounds at"/>
</results>
